Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 9/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | MARS1 | P56192 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2968713 | 0.82 | ALDH1A1 (0.48) | ALDH1A1PKMP2RX7CHRNB2CHRNA4 | |
| SCHEMBL6358757 | 0.80 | LMNA (0.55) | CHRNB2CHRNA4 | |
| SCHEMBL7508760 | 0.78 | P2RX7 (0.52) | ALDH1A1PKMP2RX7CHRNB2CHRNA4 | |
| SCHEMBL6358471 | 0.70 | ALDH1A1 (0.48) | ALDH1A1PKMP2RX7CHRNB2CHRNA4 | |
| SCHEMBL7503535 | 0.68 | CHRNA7 (0.48) | CHRNB2CHRNA4CYP11B1 | |
| SCHEMBL6360177 | 0.68 | ALDH1A1 (0.53) | ALDH1A1PKMP2RX7CHRNB2CHRNA4 | |
| SCHEMBL7510438 | 0.67 | ALDH1A1 (0.64) | ALDH1A1PKMP2RX7CHRNB2CHRNA4 | |
| SCHEMBL42240 | 0.66 | — | — | |
| SCHEMBL25205149 | 0.66 | NR3C1 (0.47) | ALDH1A1PKMP2RX7TRPA1SIGMAR1 | |
| SCHEMBL25234793 | 0.66 | GRIN2B (0.54) | ALDH1A1PKMP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250806-A1 | Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | PFIZER INC | 2005-11-10 | — | — | US | claimed |
| US-20030134844-A1 | Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | PFIZER INC. | 2003-07-17 | — | — | US | claimed |
| EP-0857725-B1 | (N-(pyridinylmethyl)-heterocyclic)-ylideneamine compounds as nicotinic acetylcholine receptor binding agents | PFIZER (US) | 2001-07-25 | — | — | EP | claimed |
| US-6020335-A | (N-(pyridinylmethyl)-heterocyclic)ylideneamine compounds as nicotinic acetylcholine receptor binding agents | PFIZER INC (US) | 2000-02-01 | — | — | US | claimed |
| EP-0857725-A1 | (N-(pyridinylmethyl)-heterocyclic)-ylideneamine compounds as nicotinic acetylcholine receptor binding agents | PFIZER INC. (US) | 1998-08-12 | — | — | EP | claimed |
| US-20050250806-A1 | Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | PFIZER INC | 2005-11-10 | — | — | US | disclosed |
| EP-1439836-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS IN THE TREATMENT OF RESTLESS LEGS SYNDROME | Pfizer Products Inc. (US) | 2004-07-28 | — | — | EP | disclosed |
| US-20030134844-A1 | Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | PFIZER INC. | 2003-07-17 | — | — | US | disclosed |
| WO-2003037329-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS IN THE TREATMENT OF RESTLESS LEGS SYNDROME | PFIZER PRODUCTS INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| EP-0857725-B1 | (N-(pyridinylmethyl)-heterocyclic)-ylideneamine compounds as nicotinic acetylcholine receptor binding agents | PFIZER (US) | 2001-07-25 | — | — | EP | disclosed |
| US-6020335-A | (N-(pyridinylmethyl)-heterocyclic)ylideneamine compounds as nicotinic acetylcholine receptor binding agents | PFIZER INC (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0857725-A1 | (N-(pyridinylmethyl)-heterocyclic)-ylideneamine compounds as nicotinic acetylcholine receptor binding agents | PFIZER INC. (US) | 1998-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134844-A1 | Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | CHRNA5, CHRNA1, CHRNA7 | ALDH1A1 2718/4885PKM 3444/4885P2RX7 74/4885 |
| US-20050250806-A1 | Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | CHRNA5, CHRNA1, CHRNA2 | ALDH1A1 2690/4885PKM 2939/4885P2RX7 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.